Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | F7 | P08709 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.42 |
| ▸ | PLAU | P00749 | 4/20 | 0.42 |
| ▸ | PLG | P00747 | 3/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314492 | 0.89 | F10 (0.48) | F2F10F7PRSS1PLAU | |
| SCHEMBL8329299 | 0.88 | F2 (0.48) | F2F10F7PRSS1PLAU | |
| SCHEMBL4316759 | 0.88 | TPSAB1 (0.48) | F2F10F7PRSS1PLAU | |
| SCHEMBL7408229 | 0.85 | F2 (0.59) | F2F10F7PRSS1PLAU | |
| SCHEMBL5303343 | 0.78 | PDE10A (0.43) | F2F10F7PRSS1PLAU | |
| SCHEMBL21067335 | 0.77 | F10 (0.61) | F2F10F7PRSS1PLAU | |
| SCHEMBL9023171 | 0.77 | F10 (0.48) | F2F10F7PRSS1PLAU | |
| SCHEMBL29730336 | 0.77 | F2 (0.71) | F2F10F7PRSS1PLAU | |
| SCHEMBL3417204 | 0.75 | CCND3 (0.60) | — | |
| SCHEMBL7405355 | 0.75 | F10 (0.51) | F2F10F7PRSS1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0973750-B1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | UNIV NORTH CAROLINA (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0831832-B1 | METHODS OF COMBATTING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES | UNIV NORTH CAROLINA (US) | 2003-12-17 | — | — | EP | claimed |
| EP-0973750-A1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | The University of North Carolina at Chapel Hill (US) | 2000-01-26 | — | — | EP | claimed |
| US-5972969-A | TREATING CANDIDA ALBICANS AND CRYPTOCOCCUS NEOFORMANS INFECTIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-10-26 | — | — | US | claimed |
| US-5939440-A | FUNGICIDES AND BACTERICIDES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998038170-A1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-03 | — | — | WO | claimed |
| US-5792782-A | TREATING CRYPTOCOCCUS NEOFORMANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-08-11 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| WO-1996040145-A1 | METHODS OF COMBATTING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | F2 4176/4885F10 4333/4885F7 4639/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | F2 2085/4885F10 2519/4885F7 3348/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | F2 3907/4885F10 3617/4885F7 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.